JPH08507767A - 管脈形成を抑制する方法および組成物 - Google Patents
管脈形成を抑制する方法および組成物Info
- Publication number
- JPH08507767A JPH08507767A JP6520046A JP52004694A JPH08507767A JP H08507767 A JPH08507767 A JP H08507767A JP 6520046 A JP6520046 A JP 6520046A JP 52004694 A JP52004694 A JP 52004694A JP H08507767 A JPH08507767 A JP H08507767A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- compound
- human
- group
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2504693A | 1993-03-01 | 1993-03-01 | |
US08/025,046 | 1993-03-01 | ||
US08/168,817 | 1993-12-15 | ||
US08/168,817 US5629327A (en) | 1993-03-01 | 1993-12-15 | Methods and compositions for inhibition of angiogenesis |
PCT/US1994/001971 WO1994020085A1 (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001050214A Division JP4065373B2 (ja) | 1993-03-01 | 2001-02-26 | サリドマイドを有効成分とする医薬品製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08507767A true JPH08507767A (ja) | 1996-08-20 |
Family
ID=26699202
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6520046A Withdrawn JPH08507767A (ja) | 1993-03-01 | 1994-02-24 | 管脈形成を抑制する方法および組成物 |
JP2001050214A Expired - Lifetime JP4065373B2 (ja) | 1993-03-01 | 2001-02-26 | サリドマイドを有効成分とする医薬品製剤 |
JP2004220584A Pending JP2004359693A (ja) | 1993-03-01 | 2004-07-28 | サリドマイドを有効成分とする医薬品製剤 |
JP2007289175A Pending JP2008088182A (ja) | 1993-03-01 | 2007-11-07 | サリドマイドを有効成分とする医薬品製剤 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001050214A Expired - Lifetime JP4065373B2 (ja) | 1993-03-01 | 2001-02-26 | サリドマイドを有効成分とする医薬品製剤 |
JP2004220584A Pending JP2004359693A (ja) | 1993-03-01 | 2004-07-28 | サリドマイドを有効成分とする医薬品製剤 |
JP2007289175A Pending JP2008088182A (ja) | 1993-03-01 | 2007-11-07 | サリドマイドを有効成分とする医薬品製剤 |
Country Status (20)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506861A (ja) * | 1998-03-16 | 2002-03-05 | コルジーン コーポレイション | 2−(2,6−ジオキソピペリジン−3−イル)イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
JP2002514578A (ja) * | 1998-05-11 | 2002-05-21 | エントレメッド インコーポレイテッド | 2−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用 |
JP2004538322A (ja) * | 2001-08-06 | 2004-12-24 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
JP2009509945A (ja) * | 2005-09-27 | 2009-03-12 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子の放出を抑制できる5H−チエノ[3,4−c]ピロール−4,6ジオン誘導物 |
JP2009538318A (ja) * | 2006-05-26 | 2009-11-05 | セルジーン・コーポレーション | 併用療法において免疫調節化合物を用いる方法及び組成物 |
Families Citing this family (286)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6805865B1 (en) | 1993-05-27 | 2004-10-19 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
US20040248799A1 (en) * | 1993-05-27 | 2004-12-09 | Holaday John W. | Compositions and methods for treating cancer and hyperproliferative disorders |
DE4422237A1 (de) | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6440729B1 (en) * | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
JP3263598B2 (ja) * | 1995-11-01 | 2002-03-04 | 有限会社ドット | 経鼻吸収用生理活性ペプチド組成物 |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
EP2859895A1 (en) * | 1996-07-24 | 2015-04-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
EP2070920B8 (en) * | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
ES2253787T3 (es) * | 1996-11-05 | 2006-06-01 | The Children's Medical Center Corporation | Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid. |
US6028060A (en) * | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
US5981508A (en) * | 1997-01-29 | 1999-11-09 | Vanderbilt University | Facilitation of repair of neural injury with CM101/GBS toxin |
US5858991A (en) * | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
US6670337B1 (en) | 1998-01-29 | 2003-12-30 | Yeda Reaearch And Development Co., Ltd. | Facilitation of wound healing with CM101/GBS toxin |
US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
US5994388A (en) * | 1997-03-18 | 1999-11-30 | The Children's Medical Center Corporation | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis |
WO1998042722A1 (en) | 1997-03-21 | 1998-10-01 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
US6174695B1 (en) | 1997-08-12 | 2001-01-16 | The Regents Of The University Of California | Epoxide hydrolase inhibitor methods |
CA2302017C (en) | 1997-08-25 | 2007-01-30 | Harold Brem | Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
PT1308444E (pt) * | 1997-11-18 | 2006-08-31 | Celgene Corp | 2-( 2,6-dioxo-3-fluoropiperidina-3-il )- isoindolinas e a sua utilizacao para reduzir os niveis de tnf |
WO1999058126A1 (en) | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US8609614B2 (en) | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
US6576613B1 (en) * | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
US6703050B1 (en) * | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
AU5991699A (en) | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
US6231889B1 (en) | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
US6596690B2 (en) * | 1998-10-06 | 2003-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vasostatin as marrow protectant |
FR2784580B1 (fr) | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
US7238711B1 (en) * | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
WO2000041547A2 (en) * | 1999-01-13 | 2000-07-20 | The Rockefeller University | Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
AU771015B2 (en) | 1999-03-18 | 2004-03-11 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
EP1040838B1 (de) | 1999-03-31 | 2003-03-26 | Grünenthal GmbH | Stabile wässrige Lösung von 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6673843B2 (en) | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
US6916843B1 (en) * | 1999-08-11 | 2005-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids |
US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
WO2001037873A2 (en) | 1999-11-10 | 2001-05-31 | Lentz M Rigdon | Method and system to remove cytokine inhibitor in patients |
US6204270B1 (en) * | 1999-11-12 | 2001-03-20 | Eyal S. Ron | Ophthalmic and mucosal preparations |
WO2001036604A2 (en) | 1999-11-18 | 2001-05-25 | Corvas International, Inc. | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
WO2001041755A2 (en) * | 1999-12-02 | 2001-06-14 | The Regents Of The University Of Michigan | Topical compositions comprising thalidomide for the treatment of inflammatory diseases |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
CN1121218C (zh) * | 2000-03-08 | 2003-09-17 | 台湾东洋药品工业股份有限公司 | 酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用 |
US8697137B2 (en) | 2000-03-24 | 2014-04-15 | Biosphere Medical, Inc. | Methods of using microspheres for active embolization |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
WO2001074362A1 (en) * | 2000-03-31 | 2001-10-11 | Celgene Corporation | Inhibition of cyclooxygenase-2 activity |
CA2408707C (en) | 2000-05-15 | 2010-04-13 | Celgene Corp. | Compositions and methods for the treatment of cancer |
NZ522766A (en) * | 2000-05-15 | 2005-09-30 | Celgene Corp | Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects |
US20030104573A1 (en) * | 2000-09-11 | 2003-06-05 | Shimkets Richard A. | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
JP4242651B2 (ja) * | 2000-11-30 | 2009-03-25 | ザ チルドレンズ メディカル センター コーポレイション | 4−アミノ−サリドマイドエナンチオマーの合成法 |
US20040121945A1 (en) * | 2000-12-15 | 2004-06-24 | Hong Liang | Compositions and methods for inhibiting endothelial cell proliferation |
EP1226824A1 (en) * | 2001-01-24 | 2002-07-31 | TTY Biopharm Company Limited | Use of thalidomide for the treatment of hepatocellular carcinoma |
US6632835B2 (en) | 2001-02-22 | 2003-10-14 | Nanodesign Inc. | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents |
EP1389203B8 (en) * | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
CA2444704C (en) * | 2001-04-23 | 2012-07-10 | University Of Virginia Patent Foundation | Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents |
JP2005504037A (ja) * | 2001-07-27 | 2005-02-10 | ユニヴァースティ オブ カンザス メディカル センター | Iv型コラーゲンnc1ドメイン六量体の結晶化構造 |
GB0125659D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Spermicides |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
DK1572169T3 (da) * | 2002-03-08 | 2013-10-21 | Shanghai Inst Biol Sciences | Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf |
US20060229239A9 (en) * | 2002-03-08 | 2006-10-12 | Mamoru Shoji | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
WO2003086283A2 (en) * | 2002-04-09 | 2003-10-23 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
WO2003097052A2 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
US20060142203A1 (en) * | 2002-06-26 | 2006-06-29 | Todd Hembrough | Compositions and methods comprising protein activated receptor antagonists |
ES2358730T3 (es) | 2002-07-15 | 2011-05-13 | Board Of Regents, The University Of Texas System | Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer. |
CA2493544A1 (en) * | 2002-07-22 | 2004-01-29 | Chemgenex Pharmaceuticals, Inc. | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
EA008683B1 (ru) * | 2002-07-23 | 2007-06-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
ZA200503024B (en) * | 2002-10-15 | 2006-11-29 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
CA2504024A1 (en) * | 2002-10-31 | 2004-05-21 | Celgene Corporation | Composition for the treatment of macular degeneration |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
NZ564480A (en) | 2002-11-06 | 2008-12-24 | Celgene Corp | Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
BR0316206A (pt) * | 2002-11-12 | 2005-09-27 | Alcon Inc | Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos |
US7230012B2 (en) | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7517887B2 (en) * | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
US7868011B2 (en) * | 2003-04-09 | 2011-01-11 | General Atomics | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus |
US7196093B2 (en) * | 2003-04-09 | 2007-03-27 | General Atomics | Reversible inhibitors of SAH hydrolase and uses thereof |
DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
AU2004275693A1 (en) * | 2003-05-28 | 2005-04-07 | Entremed, Inc. | Antiangiogenic agents |
WO2005016326A2 (en) * | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
SG133603A1 (en) * | 2003-09-17 | 2007-07-30 | Us Gov Health & Human Serv | Thalidomide analogs as tnf-alpha modulators |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
AU2003286931A1 (en) * | 2003-11-06 | 2004-06-06 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
JP2007510670A (ja) * | 2003-11-06 | 2007-04-26 | セルジーン・コーポレーション | サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物 |
CN1913896B (zh) * | 2003-12-02 | 2010-12-01 | 细胞基因公司 | 用于治疗和控制血红蛋白病和贫血病的方法和组合物 |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
US7430276B2 (en) * | 2004-02-25 | 2008-09-30 | Nanodynamics-88 | Low dose X-ray mammography method |
AU2005222934B2 (en) * | 2004-03-12 | 2010-06-17 | Entremed, Inc. | Antiangiogenic agents |
CN1956718A (zh) * | 2004-03-22 | 2007-05-02 | 细胞基因公司 | 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法 |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
MXPA06011798A (es) * | 2004-04-14 | 2007-01-16 | Celgene Corp | Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos. |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
BRPI0510110A (pt) * | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
ZA200609227B (en) * | 2004-04-23 | 2008-06-25 | Celgene Corp | Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension |
JP2008511340A (ja) * | 2004-04-30 | 2008-04-17 | バイオフェレシス テクノロジーズ, インコーポレイテッド | 患者において可溶性tnfr1、可溶性tnfr2、および可溶性il2を除去する方法およびシステム |
US7273890B1 (en) * | 2004-06-08 | 2007-09-25 | Sagittarius Life Science Corp. | ST104P, an anti-angiogenic agent |
EP1778652A2 (en) * | 2004-08-20 | 2007-05-02 | EntreMed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
BRPI0518282A2 (pt) * | 2004-11-23 | 2008-11-11 | Celgene Corp | uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio |
ES2568782T3 (es) | 2005-05-09 | 2016-05-04 | Biosphere Medical, S.A. | Composiciones y métodos de uso de microesferas y agentes de contraste no iónicos |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
US20080167272A1 (en) * | 2005-06-16 | 2008-07-10 | Auckland Uniservices Limited | Thalidomide metabolites and methods of use |
PT2380887E (pt) * | 2005-06-30 | 2013-09-18 | Celgene Corp | Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona |
US20080279912A1 (en) * | 2005-07-12 | 2008-11-13 | Regents Of The University Of California Office Of Technology Transfer | Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
AU2006301292A1 (en) * | 2005-10-14 | 2007-04-19 | F. Hoffmann-La Roche Ag | Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
EP1986707A2 (en) | 2006-01-30 | 2008-11-05 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
WO2007090130A2 (en) * | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
WO2007109312A2 (en) * | 2006-03-20 | 2007-09-27 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
US20070226632A1 (en) * | 2006-03-21 | 2007-09-27 | Nokia Corporation | Method, electronic device and computer program product for enhancing contact list functionality |
AU2007238785B2 (en) * | 2006-04-13 | 2013-02-07 | Agnieszka Ambrozak | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
US20080051431A1 (en) * | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008011513A2 (en) | 2006-07-19 | 2008-01-24 | The Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
CN101138634A (zh) | 2006-09-07 | 2008-03-12 | 于保法 | 用于治疗肿瘤的组合物 |
US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
EP2114898A2 (en) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
EP2136831B1 (en) | 2007-03-02 | 2012-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
US20090068236A1 (en) * | 2007-04-13 | 2009-03-12 | Chemgenex Pharmaceuticals, Inc. | Oral Cephalotaxine Dosage Forms |
WO2009020590A1 (en) | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
BRPI0815368A2 (pt) | 2007-08-21 | 2015-02-10 | Amgen Inc | "proteinas c-fms humanas a antigeno" |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US11331294B2 (en) | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
WO2009042542A1 (en) * | 2007-09-26 | 2009-04-02 | Indiana University Research And Technology Corporation | Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
US20110200612A1 (en) | 2008-06-30 | 2011-08-18 | Michael Schuster | Treatment of eye diseases and excessive neovascularization using combined therapy |
AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
JP2012507562A (ja) * | 2008-10-30 | 2012-03-29 | ダビド リウ | 微小球性多孔質生体適合性足場並びにその製造方法及び装置 |
PT2391355T (pt) | 2009-05-19 | 2017-02-21 | Celgene Corp | Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolino-1,3-diona |
WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
GB0914330D0 (en) | 2009-08-17 | 2009-09-30 | Univ Dublin City | A method of predicting response to thalidomide in multiple myeloma patients |
WO2011038139A1 (en) | 2009-09-23 | 2011-03-31 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
KR20160035613A (ko) | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
JP6069312B2 (ja) | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
ES2671608T3 (es) | 2012-02-21 | 2018-06-07 | Celgene Corporation | Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2014004990A2 (en) * | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
EP2954330A4 (en) | 2013-02-08 | 2016-08-31 | Inst Myeloma & Bone Cancer Res | IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA B-CELL LYMPHOMA |
AU2014217485B2 (en) | 2013-02-13 | 2017-02-16 | Cartiheal (2009) Ltd | Solid substrates for mitigating or preventing cell and tissue adhesion and vascularization |
US10238690B2 (en) | 2013-03-15 | 2019-03-26 | Celgene Corporation | Modified T lymphocytes comprising an inducible caspase and methods of apoptosis |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
EP4233870A3 (en) | 2014-05-28 | 2024-01-24 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
RS64038B1 (sr) | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
PT3643709T (pt) | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Ltd | Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos |
SG11201704175WA (en) | 2014-11-26 | 2017-06-29 | Baofa Yu | Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy |
US20190004048A1 (en) | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
EP3313818B1 (en) | 2015-06-26 | 2023-11-08 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
EP3324965A4 (en) | 2015-07-24 | 2019-07-03 | Oncotracker, Inc. | MODULATORS OF GAMMA-SECRETASE FOR THE TREATMENT OF MALFUNCTIONS OF THE IMMUNE SYSTEM |
AU2016330967B2 (en) * | 2015-09-30 | 2021-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thalidomide analogs and methods of use |
CA3001799A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
WO2017173290A1 (en) * | 2016-03-31 | 2017-10-05 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
BR112019011065A2 (pt) | 2016-12-03 | 2019-10-01 | Juno Therapeutics Inc | métodos para determinação da dosagem de células t car |
WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
EP3576726A1 (en) | 2017-02-06 | 2019-12-11 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
IL310031A (en) | 2017-05-01 | 2024-03-01 | Juno Therapeutics Inc | A combination of cellular therapy and an immune modulatory compound |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
AU2018275894A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
EP3639028A4 (en) | 2017-06-13 | 2021-04-14 | Inc. Onco Tracker | DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MALIGNE SOLID TUMORS |
CA3067602A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
US11623961B2 (en) | 2017-11-01 | 2023-04-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
JP2021508317A (ja) | 2017-12-01 | 2021-03-04 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞の投与および調節のための方法 |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
WO2019210080A1 (en) * | 2018-04-25 | 2019-10-31 | The Regents Of The University Of California | Methods and compositions for skeletal and neurological disorders |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3790886A1 (en) | 2018-05-10 | 2021-03-17 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
EP3830093A1 (en) | 2018-07-27 | 2021-06-09 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
US20220008477A1 (en) | 2018-11-08 | 2022-01-13 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
CR20210387A (es) | 2018-12-20 | 2021-08-19 | Amgen Inc | Inhibidores de kif18a |
US20220056015A1 (en) | 2018-12-20 | 2022-02-24 | Amgen Inc. | Kif18a inhibitors |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
JP2022514268A (ja) | 2018-12-20 | 2022-02-10 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
US20220096651A1 (en) | 2019-01-29 | 2022-03-31 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
AU2020383535A1 (en) | 2019-11-14 | 2022-05-05 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
AU2020381492A1 (en) | 2019-11-14 | 2022-05-26 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
EP4087611A1 (en) | 2020-01-07 | 2022-11-16 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768821A (en) | 1954-05-17 | 1957-02-20 | Gruenenthal Chemie | Novel products of the amino-piperidine-2, 6-dione series |
US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
US3142672A (en) * | 1957-09-03 | 1964-07-28 | Takeda Pharmaceutical | Derivatives of nu-alpha-phenyl-and nu-alpha-biphenylylbutyric acids and amino sugars |
US3560495A (en) * | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
US3563986A (en) * | 1965-10-12 | 1971-02-16 | Ernst Frankus | 4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6 |
DE1670551B2 (de) * | 1965-10-30 | 1973-01-25 | Salze trisubstituierter s-triazine | |
AT278739B (de) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren |
US3705162A (en) * | 1967-07-01 | 1972-12-05 | Gruenenthal Chemie | 4-phthalimidine glutarimides |
FI830078L (fi) * | 1982-01-15 | 1983-07-16 | Lilly Co Eli | Askorbinsyraetrar och liknande foereningar |
US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
JP2544136B2 (ja) * | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤 |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
DE68910138T2 (de) * | 1988-01-19 | 1994-04-28 | Takeda Chemical Industries Ltd | Fumagillin als angiostatisches Mittel. |
AT393221B (de) * | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken |
US5021404A (en) * | 1988-04-20 | 1991-06-04 | The Children's Medical Center Corporation | Angiostatic collagen modulators |
ES2053890T3 (es) * | 1988-09-01 | 1994-08-01 | Takeda Chemical Industries Ltd | Agente inhibidor de la angiogenesis. |
US5049154A (en) * | 1989-08-07 | 1991-09-17 | Berkshire Research & Development, Inc. | Adjustable intra-luminal valvulotome |
JPH03109324A (ja) * | 1989-09-22 | 1991-05-09 | Microbial Chem Res Found | 血管新生阻害剤 |
GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5405851A (en) * | 1990-06-19 | 1995-04-11 | Burroughs Wellcome Co. | Pharmaceutical compounds |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
ES2098505T3 (es) * | 1991-04-17 | 1997-05-01 | Gruenenthal Chemie | Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. |
US5679696A (en) | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
DE4320157A1 (de) | 1993-06-18 | 1994-12-22 | Bayer Ag | Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
AU7376494A (en) | 1993-08-04 | 1995-02-28 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
US5405855A (en) | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US5443824A (en) | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
DE69633040T2 (de) * | 1995-03-17 | 2004-12-09 | Toray Industries, Inc. | Inhibitor der hornhaut-vaskularisation |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
AU771015B2 (en) | 1999-03-18 | 2004-03-11 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
-
1993
- 1993-12-15 US US08/168,817 patent/US5629327A/en not_active Expired - Lifetime
-
1994
- 1994-02-24 CA CA2512926A patent/CA2512926C/en not_active Expired - Lifetime
- 1994-02-24 CA CA002342974A patent/CA2342974C/en not_active Expired - Lifetime
- 1994-02-24 JP JP6520046A patent/JPH08507767A/ja not_active Withdrawn
- 1994-02-24 EP EP94909773A patent/EP0688211B1/en not_active Expired - Lifetime
- 1994-02-24 DE DE69430796T patent/DE69430796T2/de not_active Expired - Lifetime
- 1994-02-24 EP EP02012280A patent/EP1245229A3/en not_active Withdrawn
- 1994-02-24 NZ NZ535670A patent/NZ535670A/en not_active IP Right Cessation
- 1994-02-24 NZ NZ262676A patent/NZ262676A/xx not_active IP Right Cessation
- 1994-02-24 EP EP05002523A patent/EP1537870A3/en not_active Withdrawn
- 1994-02-24 AT AT94909773T patent/ATE218865T1/de active
- 1994-02-24 DE DE69434490T patent/DE69434490T2/de not_active Expired - Lifetime
- 1994-02-24 ES ES94909773T patent/ES2174873T3/es not_active Expired - Lifetime
- 1994-02-24 AU AU62486/94A patent/AU676722B2/en not_active Expired
- 1994-02-24 DE DE122008000044C patent/DE122008000044I2/de active Active
- 1994-02-24 ES ES02011928T patent/ES2245711T3/es not_active Expired - Lifetime
- 1994-02-24 CA CA002157288A patent/CA2157288C/en not_active Expired - Lifetime
- 1994-02-24 PT PT94909773T patent/PT688211E/pt unknown
- 1994-02-24 AT AT02011928T patent/ATE304356T1/de not_active IP Right Cessation
- 1994-02-24 WO PCT/US1994/001971 patent/WO1994020085A1/en active IP Right Grant
- 1994-02-24 DK DK94909773T patent/DK0688211T3/da active
- 1994-02-24 DK DK02011928T patent/DK1264597T3/da active
- 1994-02-24 NZ NZ336527A patent/NZ336527A/en not_active IP Right Cessation
- 1994-02-24 NZ NZ535671A patent/NZ535671A/en not_active IP Right Cessation
- 1994-02-24 EP EP02011928A patent/EP1264597B1/en not_active Revoked
- 1994-02-24 KR KR1019950703700A patent/KR100506043B1/ko not_active IP Right Cessation
- 1994-03-01 BR BR9400764A patent/BR9400764A/pt not_active Application Discontinuation
- 1994-03-01 CO CO94008093A patent/CO4230017A1/es unknown
- 1994-03-01 PE PE1994237564A patent/PE10095A1/es not_active Application Discontinuation
-
1995
- 1995-01-13 US US08/371,987 patent/US5593990A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,792 patent/US5712291A/en not_active Ceased
-
1997
- 1997-08-22 US US08/918,610 patent/US6235756B1/en not_active Expired - Lifetime
- 1997-10-16 US US08/950,673 patent/US6071948A/en not_active Expired - Lifetime
-
2000
- 2000-04-07 US US09/545,139 patent/US6469045B1/en not_active Expired - Fee Related
- 2000-11-09 US US09/710,533 patent/US6420414B1/en not_active Expired - Lifetime
-
2001
- 2001-02-26 JP JP2001050214A patent/JP4065373B2/ja not_active Expired - Lifetime
- 2001-07-05 US US09/899,318 patent/US20010056113A1/en not_active Abandoned
- 2001-09-28 US US09/966,895 patent/US20020049231A1/en not_active Abandoned
- 2001-10-24 US US10/001,183 patent/US20020119956A1/en not_active Abandoned
- 2001-12-12 US US10/015,252 patent/US20020052398A1/en not_active Abandoned
- 2001-12-19 US US10/026,037 patent/US6977268B2/en not_active Expired - Fee Related
- 2001-12-20 US US10/026,291 patent/US20020061911A1/en not_active Abandoned
-
2002
- 2002-06-11 US US10/167,531 patent/US20020161024A1/en not_active Abandoned
- 2002-12-13 US US10/319,389 patent/US20030187024A1/en not_active Abandoned
-
2003
- 2003-01-14 US US10/341,928 patent/US20030176463A1/en not_active Abandoned
- 2003-06-10 HK HK03104072A patent/HK1052865A1/xx not_active IP Right Cessation
-
2004
- 2004-07-28 JP JP2004220584A patent/JP2004359693A/ja active Pending
-
2005
- 2005-03-31 US US11/096,155 patent/US7723361B2/en not_active Expired - Fee Related
-
2006
- 2006-09-22 US US11/525,346 patent/US8012996B2/en not_active Expired - Fee Related
-
2007
- 2007-11-07 JP JP2007289175A patent/JP2008088182A/ja active Pending
-
2008
- 2008-08-01 FR FR08C0036C patent/FR08C0036I2/fr active Active
- 2008-08-20 LU LU91471C patent/LU91471I2/fr unknown
- 2008-09-01 NL NL300358C patent/NL300358I2/nl unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506861A (ja) * | 1998-03-16 | 2002-03-05 | コルジーン コーポレイション | 2−(2,6−ジオキソピペリジン−3−イル)イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
JP2011042674A (ja) * | 1998-03-16 | 2011-03-03 | Celgene Corp | 2−(2,6−ジオキソピペリジン−3−イル)イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
JP4695259B2 (ja) * | 1998-03-16 | 2011-06-08 | セルジーン コーポレイション | 2−(2,6−ジオキソピペリジン−3−イル)イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
JP2002514578A (ja) * | 1998-05-11 | 2002-05-21 | エントレメッド インコーポレイテッド | 2−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用 |
JP2004538322A (ja) * | 2001-08-06 | 2004-12-24 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
JP2009509945A (ja) * | 2005-09-27 | 2009-03-12 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子の放出を抑制できる5H−チエノ[3,4−c]ピロール−4,6ジオン誘導物 |
JP2009538318A (ja) * | 2006-05-26 | 2009-11-05 | セルジーン・コーポレーション | 併用療法において免疫調節化合物を用いる方法及び組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08507767A (ja) | 管脈形成を抑制する方法および組成物 | |
JP5066505B2 (ja) | 血管形成抑制のための方法と組成物 | |
US6518298B2 (en) | Methods and compositions for inhibition of angiogenesis with EM-138 | |
USRE40360E1 (en) | Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide | |
US20010056114A1 (en) | Methods for the inhibition of angiogenesis with 3-amino thalidomide | |
US20120142734A1 (en) | Methods for treating tumors with thalidomide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041022 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20041022 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060106 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060525 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060606 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060825 |